Four Readers, Four Reasons to Try GHK-Cu The protocol that follows is calibrated for four overlapping reader profiles
Human evidence remains limited to small panels and cosmetic-grade applications
Cagrilintide vs tirzepatide (Mounjaro/Zepbound) Mechanism: Cagrilintide: Amylin agonist Tirzepatide: Dual GIP/GLP-1 agonist Both novel approaches Weight loss: Cagrilintide: 10-12% monotherapy Tirzepatide: 15-22% monotherapy Tirzepatide superior as single agent Administration: Both: Weekly subcutaneous injection Both: Similar convenience Side effects: Cagrilintide: Strong GI effects Tirzepatide: Moderate GI effects Similar overall profile Approval status: Cagrilintide: Investigational Tirzepatide: FDA approved Tirzepatide available now Cost (when both available): Likely similar ($1,000-1,500/month) Both premium weight loss options Verdict: Currently, tirzepatide better choice (approved, superior weight loss)
Improves Cardiac Function: Increases cardiac output and left ventricular function independently of GH, likely through myocardial GHS-R1a activation 3
Cloudiness, visible particles, discoloration, or obvious container damage all point to a vial that no longer matches its labeled state